IF anti-IL-11 neutralizing antibody (X203 or equivalent, subcutaneous, 20 mg/kg bi-weekly — consistent with Widjaja et al. 2024 dosing in aged mice) is administered to 18–24-month-old male and female C57BL/6J mice carrying a p16-luciferase or p16-tdTomato reporter transgene,

THEN a statistically significant reduction (≥30%) in p16INK4a+ cell counts across liver, kidney, lung, and adipose tissue — quantified by flow cytometry of dissociated tissue and validated by in vivo bioluminescent imaging — will be observed relative to vehicle-treated aged controls, with this reduction exceeding what is achievable by a benchmark senomorphic agent (MDM2 inhibitor nutlin-3a at senomorphic dose) that suppresses SASP without reducing senescent cell number,

BECAUSE the following mechanistic chain operates:

1. Senescent cells in aged tissues produce IL-11 as part of the SASP, creating an autocrine/paracrine IL-11→gp130→ERK signaling loop [SPECULATIVE — no direct DOI in Evidence Set for IL-11 as autocrine SASP factor; supported by the general SCAP framework described in the translational senescence review establishing that pro-survival pathways can be identified by transcriptional profiling of senescent cells] (Senescent Cell Anti-Apoptotic Pathways framework)(https://doi.org/10.1016/j.ebiom.2017.04.013).

2. This ERK activation downstream of IL-11/gp130 feeds directly into RAS signaling, which has been mechanistically demonstrated to sustain oxylipin biosynthesis — specifically the dihomo-15d-PGJ2/PGD2-derived lipid axis — creating a positive feedback loop that reinforces both the senescent arrest and key SASP components (Oxylipin-RAS-p53 reinforcement of senescent state)(https://doi.org/10.1016/j.cmet.2021.03.008).

3. This oxylipin→RAS→p53 positive feedback constitutes a functional component of a Senescent Cell Anti-Apoptotic Pathway (SCAP): disrupting its upstream initiator (IL-11) collapses the autocrine reinforcement, withdrawing a critical pro-survival signal and sensitizing senescent cells to apoptosis rather than merely dampening cytokine output (SCAP survival logic)(https://doi.org/10.1016/j.ebiom.2017.04.013).

4. Crucially, a validated senomorphic control — MDM2 inhibition at sub-senolytic dose — has been experimentally demonstrated to suppress SASP without reducing senescent cell number or reversing cell-cycle arrest, confirming the mechanistic separability of SASP suppression from cell clearance (senomorphic MDM2 inhibition distinction)(https://doi.org/10.1101/2023.11.20.567963). Anti-IL-11 antibody, by targeting the SCAP loop rather than directly modulating p53 transcriptional activity, is predicted to cross the cell-death threshold that senomorphic MDM2 inhibition does not.

5. Network-based transcriptomic analyses of senescent cells have identified novel SCAPs — including ERK-dependent survival nodes — that represent targetable vulnerabilities; disrupting these nodes causes senolysis rather than mere SASP attenuation (transcriptomic SCAP ide...

SENS category: LysoSENS

Key references: • doi.org/10.1016/j.ebiom.2017.04.013 • doi.org/10.1016/j.cmet.2021.03.008 • doi.org/10.1101/2023.11.20.567963 • doi.org/10.1101/2024.05.28.596326 • doi.org/10.15252/embj.201592862